Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Cash flow from operating activities:
Net loss	$ 49,938	$ (46,325)	$ (96,078)	$ (212,143)	$ (208,233)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation and amortization			6,211	6,341
Deferred income taxes			(1,356)	(8,402)
Impairment on acquired IPR&D		129,400		129,400
Provision for doubtful accounts			113	1,005
Share-based compensation expense			38,077	3,355
(Income) expense related to warrant liabilities			(2,258)	52,065
Change in fair value of contingent consideration			(17,845)	(26,136)
Loss on sale of business, net of tax		4,434		4,434
Other, net			3,206	(41)
Changes in assets and liabilities:
Accounts receivable			(754)	1,465
Inventory			(3,778)	(745)
Prepaid expenses and other assets			(1,522)	(5,336)
Sale of NOL and R&D tax credits			1,356	3,765
Accounts payable			1,364	237
Accrued expenses and other liabilities			3,846	(939)
Deferred revenue			(8,633)	5,313
Net cash used in operating activities			(78,051)	(46,362)
Cash flow from investing activities:
Capital expenditures			(3,900)	(18,462)
Proceeds from promissory note			300
Proceeds from sale of business				15,019
Net cash used in investing activities			(3,600)	(3,443)
Cash flow from financing activities:
Proceeds from issuance of Series B redeemable convertible preferred stock and warrants, net of issuance costs				102,535
Repurchase of common stock				(256)
Proceeds from short term borrowings - related party			5,000
Payment of short term borrowings - related party			(5,000)
Proceeds from the exercise of stock options			223	52
Proceeds from PIPE financing			83,400
Proceeds from Palantir investment			20,000
Payments of PIPE/SPAC related costs			(9,433)
Net cash provided by financing activities			99,576	102,331
Net increase in cash, cash equivalents and restricted cash			17,925	52,526
Cash, cash equivalents and restricted cash at beginning of period			69,513	43,507	43,507
Cash, cash equivalents and restricted cash at end of period	$ 87,438	$ 96,033	87,438	96,033	$ 69,513
Supplemental disclosure of cash flow information:
Cash paid for income taxes			11	4
Supplemental non-cash investing and financing activities:
Property and equipment included in accounts payable and accrued expenses			(1,601)	(5,153)
Conversion of Series A, Series B and Series X preferred stock into common stock			550,113
Cancellation of treasury stock			256
Issuance of common stock as payment for PIPE/merger related costs			10,795
Reclassification of warrant liabilities to equity			96,398
Issuance of convertible note in connection with the Sanuwave Transaction				4,524
Change in PIPE/SPAC related costs captured in accounts payable and accrued expenses			1,103
Commencement of capital lease obligations				(216)
UltraMIST systems reclass from inventory to fixed assets				79
Fair value of warrants issued in connection with Series B preferred stock sale				17,954
Issuance of warrants at estimated fair value				$ 11,988
Gx Acquisition Corp.
Cash flow from financing activities:
Cash received on recapitalization			5,386
Supplemental non-cash investing and financing activities:
Non-cash assets acquired from the merger			163
Warrant liability assumed from the merger			$ 59,202